Print Page     Close Window     

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
06/12/17Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
- Based on recent FDA interactions, the new SER-109 Clinical Study is to be designated a Phase 3 Trial - - SER-109 Phase 3 Trial is the first pivotal trial in the emerging field of microbiome-based oral therapeutics - - Phase 3 Trial initiation triggers a $20 million milestone payment from Nestlé Health Science - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the... 
 Printer Friendly Version
06/06/17Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will participate in a webcast discussion at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 4 p.m. PT. Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available approximately... 
 Printer Friendly Version
06/05/17Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
- Study results expected in the second half of 2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it has completed enrollment for its ongoing SER-287 Phase 1b clinical study of 58 patients suffering from mild-to-moderate ulcerative colitis who are failing current therapies. SER-287 is the first microbiome therapeutic candidate to reach clinical‐stage development in a chronic inf... 
 Printer Friendly Version
05/04/17Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress
- Pre-enrollment activities underway for SER-109 ECOSPOR III clinical study initiation; Company expects study start in mid-year - - Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Data read-outs expected in the second half of 2017 - - Conference call at 8 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2017-- Seres Therapeutics Inc. (NASDAQ:MCRB) today reported first quarter 2017 fin... 
 Printer Friendly Version
05/01/17Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017-- Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management will participate in two upcoming investor conferences: Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT. UBS Global Healthcare Conference on Monday, May 22, 2017 in New York, NY; presentation at 1:30 p.m. EDT. ... 
 Printer Friendly Version
04/28/17Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on Thursday, May 4, 2017 at 8:00 a.m. EDT to discuss first quarter 2017 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 11167224. To ... 
 Printer Friendly Version
03/16/17Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
- Positive SER-109 Type B FDA meeting - - Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements - - Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Both data read-outs expected in the second half of 2017 - - Conference call at 8 a.m. ET today - CAMBRI... 
 Printer Friendly Version
03/16/17Seres Therapeutics to Initiate New SER-109 Clinical Study
– Positive SER-109 Type B FDA meeting – – Seres and FDA reach agreement on key design elements of a new SER-109 Phase 2 study in patients with multiply recurrent C. difficile infection – – New trial may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements – – Conference call at 8 a.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- Seres Therape... 
 Printer Friendly Version
03/13/17Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, March 16, 2017 at 8:00 a.m. ET to discuss fourth quarter 2016 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (internatio... 
 Printer Friendly Version
03/02/17Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8 at 11:20 a.m. ET. Live audio webcast of the presentation be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become ava... 
 Printer Friendly Version
02/03/17Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences: Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY 6th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 15, ... 
 Printer Friendly Version
01/31/17Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses
- Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome - - FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109 - - Conference call at 8 a.m. ET today - CAMBRIDGE, Mass., January 31, 2017 —Seres Therapeutics Inc., (NASDAQ:MCRB), a leading mi... 
 Printer Friendly Version
01/30/17Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Tuesday, January 31, 2017 at 8:00 a.m. ET to discuss the results of its in-depth analyses of the previously reported SER-109 Phase 2 clinical study in patients with multiply recurrent C. difficile infection. To ac... 
 Printer Friendly Version

© Seres Therapeutics. All Rights Reserved.